Skip Navigation LinksEspañol (España) > Investigación > Publicaciones > Detalle publicación

 

 

p21Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells. p21Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells. Ferrandiz, N, Caraballo, J. M., Albajar, M, Gomez-Casares, M.T., López-Jorge, C.E., Blanco, R., Delgado, M.D. and Leon, J. Cancer Lett 292: 133-139 (2010).2010-06-14T22:00:00Z<p style="text-align:justify;"><span class="ms-rteThemeForeColor-2-5">​<span style="font-family:arial, helvetica, clean, sans-serif;font-size:1.0769em;font-weight:bold;">Abstract</span></span></p><div style="color:#000000;font-family:arial, helvetica, clean, sans-serif;text-align:justify;"><p style="margin-bottom:0.5em;font-size:1.04em;">Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21(Cip1), initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21(Cip1) expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21(Cip1) in the response to imatinib in CML.<br></p></div><p><span class="ms-rteForeColor-2"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20042273">​[pubmed]</a></span><br></p>107